Lung cancer, Non small cell lung cancer (NSCLC)
Results
Phase 2/3
This trial compared pembrolizumab with docetaxel for advanced non small cell lung cancer (NSCLC). The trial was for people:
who had already had treatment for their lung cancer with a
whose cancer cells produced a protein called PD-L1
whose cancer had grown into surrounding tissues or spread elsewhere in the body (advanced cancer)
Recruitment start: 28 February 2013
Recruitment end: 27 February 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Dean Fennell
Experimental Cancer Medicine Centre (ECMC)
Merck Sharp & Dohme Ltd
NIHR Clinical Research Network: Cancer
Last reviewed: 16 October 2018
CRUK internal database number: 10623
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
